Houston Researchers Develop Implant Device With The Potential To Treat Cancer In Just Sixty Days

Discover HAMMR, a cutting-edge implant system created by Houston researchers with the goal of curing cancer in 60 days. This ground-breaking technology could alter how cancer is treated because it functions as both a cancer detection and medicine delivery system. The expectation is that it will eventually reduce cancer fatalities by a startling 50%.

A group led by Rice University just received a $45 million federal grant to create the revolutionary cancer gadget. In Texas, 130,000 new cancer cases are identified each year, and 42,000 individuals die. The new funding organization ARPA-H, established just last year to foster research that leads to medical breakthroughs, awarded Rice the second large financing grant, which was described by Rice’s president as an honor. This team is being led by Rice University bioengineer Omid Veiseh, who is conducting extremely innovative research that has the potential to save hundreds of thousands of lives. This is the sort of study that has a big impact on the globe.

Houston Researchers Develop Device For 60-Day Cancer Treatment

The gadget is known as HAMMR (hybrid advanced molecular manufacturing regulator), and the Rice University team is known as THOR (targeted hybrid oncotherapeutic regulation). The HAMMR is an embedded gadget that can provide medicine and act as a cancer detection system. The three-inch-long implanted device has sensors to track rapidly changing cancer cells. To gain real-time insight into how our cancer cells are altering so that we can alter simultaneously.

The abdominal implant would also function as a drug production facility, producing living human cells in bio-manufacturing facilities. The researchers believe that the implant is safe. It can be programmed into whatever biologic is needed. They will be grown in a factory and loaded into the device, and when they reside in the abdomen, they’re alive, meaning they get nutrients from your body like our other cells that exist and leverage that and turn it into drugs.

The team’s expertise spans 20 distinct research labs and comprises engineers, doctors, and multidisciplinary experts in electrical engineering, artificial intelligence, synthetic biology, immunology, oncology, and materials science.

According to Veiseh, an associate professor of bioengineering at Rice, the technique is broadly relevant for peritoneal malignancies that affect the pancreas, liver, lungs, and other organs. The initial clinical research will concentrate on refractory recurrent ovarian cancer since we already have a clinical trial using our encapsulated cytokine “drug factory” technology for ovarian cancer. We will be able to expand on that knowledge. With HAMMR, we are updating the method we have shown to go from concept to clinical trial in five years. The Rice Biotech Launch Pad is a fresh effort for medical innovation and commercialization. The program, led by Veiseh, intends to quickly translate technologies found by Rice into medical therapies that eradicate illnesses and enhance quality of life.

This gadget will be capable of wireless communication, possibly with a smartphone and external charging. It enables doctors to respond to what is occurring to the cancer much quicker than it takes to acquire test results, which could take months. It works similarly to how your smartwatch charges today.

The short duration of use for the Hybrid Advanced Molecular Manufacturing Regulator (HMMR)–roughly two months—may be its most impressive feature. The goal is to cure the cancer within 60 days. Due to your training of the immune system to combat that disease, the cancer did not come back. The same principle underlies diabetic insulin pumps and implanted monitoring. Within five years, human trials are expected to begin.